Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA.
Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Sci Rep. 2018 Jul 5;8(1):10222. doi: 10.1038/s41598-018-28528-1.
RNA editing in microRNAs has been recently proposed as a novel biomarker in cancer. Here, we investigated RNA editing by leveraging small-RNA sequencing data from 87 NSCLC (Non-Small Cell Lung Cancer) samples paired with normal lung tissues from The Cancer Genome Atlas (TCGA) combined with 26 plasma-derived exosome samples from an independent cohort. Using both the editing levels and microRNA editing expression, we detected deregulated microRNA editing events between NSCLC tumor and normal tissues. Interestingly, and for the first time, we also detected editing sites in the microRNA cargo of circulating exosomes, providing the potential to non-invasively discriminate between normal and tumor samples. Of note, miR-411-5p edited in position 5 was significantly dysregulated in tissues as well as in exosomes of NSCLC patients, suggesting a potential targetome shift relevant to lung cancer biology.
RNA 编辑在 microRNAs 中最近被提出作为癌症的一种新的生物标志物。在这里，我们利用来自 87 个非小细胞肺癌 (NSCLC) 样本和来自癌症基因组图谱 (TCGA) 的配对正常肺组织的小 RNA 测序数据，以及来自独立队列的 26 个血浆衍生的外泌体样本，研究了 RNA 编辑。使用编辑水平和 microRNA 编辑表达，我们检测到 NSCLC 肿瘤和正常组织之间 microRNA 编辑事件的失调。有趣的是，也是第一次，我们还在循环外泌体的 microRNA 货物中检测到了编辑位点，为非侵入性区分正常和肿瘤样本提供了潜力。值得注意的是，在位置 5 编辑的 miR-411-5p 在组织和 NSCLC 患者的外泌体中均显著失调，提示与肺癌生物学相关的潜在靶标转移。
